Pfizer (PFE) Depreciation & Amortization (CF) (2009 - 2026)

Pfizer has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $1.6 billion for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) changed 0.31% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 29.08% YoY), while the FY2025 annual figure was $6.6 billion, down 6.0% from the prior year.
• Depreciation & Amortization (CF) eased to $1.6 billion in Q1 2026, from $1.7 billion in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for PFE reached as high as $3.5 billion in Q4 2022 and fell as low as $1.2 billion in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.6 billion (2025), against an average of $1.7 billion.
• The widest YoY moves for Depreciation & Amortization (CF): up 33.87% in 2023, down 55.99% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.5 billion in 2022, then tumbled by 52.89% to $1.7 billion in 2023, then increased by 5.09% to $1.8 billion in 2024, then declined by 3.87% to $1.7 billion in 2025, then retreated by 4.39% to $1.6 billion in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.6 billion, $1.7 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.